BRAF and neoplasm: In summary, the results of this retrospective analysis indicate that front-line CPI therapy followed by BRAF/MEKi therapy might provide better tumor control in the long-run, albeit we could only show a significant association with OS in a subgroup of previously untreated patients and not in the overall cohort of patients with BRAF-mutant, metastatic melanoma.